SciSparc subsidiary NeuroThera pursues FDA orphan drug designation for Tourette drug SCI-110
SPRC•SCI-110 program and clinical update
SCI-110 combines dronabinol with palmitoylethanolamide in a single oral dose.
A Phase IIb program is underway at three academic centers; Phase IIa showed a 21% average tic reduction on YGTSS Total Tic Score.
NeuroThera seeks orphan drug designation for SCI-110
SciSparc subsidiary NeuroThera Labs began pursuing FDA orphan drug designation for SCI-110 in adult Tourette syndrome.
NeuroThera hired RK Strategies to support the US regulatory push, stakeholder outreach, and market access positioning.
